Novartis to present Kisqali’s Phase III NATALEE study at ASCO in early-stage breast cancer – VADEMECUM

Novartis will present new data from its oncology portfolio at ASCO, including Kisqali’s Phase III NATALEE study in early-stage breast cancer

VADEMECUM – 02/05/2023
CONGRESSES / TRAINING

The primary analysis of the NATALEE study, the first and only positive Phase III study of a CDK4/6 inhibitor in a large population of patients with stages II and III HR+/HER2- early breast cancer at risk of recurrence, will be presented. including those without lymph node involvement